The Weight Loss Drugs Market is poised for significant growth from 2025 to 2035. With increasing obesity rates, rising ...

Eli Lilly & Co. is targeting additional drug compounders and telehealth companies that make copycat versions of its weight ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...

With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...

Both deputy directors at the key FDA center that oversees regulation of cancer drugs plan on leaving the agency ...

Are we truly on the brink of a cure for obesity? Or could neglecting the root causes risk worsening the very problems we seek ...

Eli Lilly's direct-to-consumer platform LillyDirect has been expanded to include in-person and telehealth services for people ...

Character Biosciences has raised $93m in an oversubscribed Series B round to speed the clinical development of a pipeline of ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The restrictions began because the FDA declared a shortage of tirzepatide, often ...

The pharma is spending $2.5 billion on an R&D center in Beijing. Elsewhere, Adaptimmune warned it could run out of cash and Pfizer sold its remaining stake in Haleon.